Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 43
Lilly's Medicare GLP-1 push: what changed
Lilly's 'A Life Covered' campaign targets the Medicare Part D exclusion for obesity drugs. Here is what the campaign asks for and what has already shifted.
Lilly obesity campaign and GLP-1 access
Lilly's new obesity campaign brings older adults into view as CMS prepares a limited Medicare GLP-1 access demonstration.
Semaglutide: body composition at 12 months
A 2026 Obesity Facts study followed 83 adults for 12 months. Semaglutide cut more weight, improved muscle quality scores, and preserved handgrip strength.
Synthetic semaglutide: the reporting gaps
Singh et al. (2026) find that synthetic semaglutide products make clinical claims the branded trial record does not support.
Tirzepatide cost of care: over-55 data
A 2026 matched cohort study found tirzepatide reduced monthly healthcare costs by $145-$319 in adults over 55 with obesity but without diabetes.
Why GLP-1 treatment response varies
A 2026 review finds no single baseline trait reliably predicts GLP-1 response. Early treatment response remains the clearest clinical signal.
Ipamorelin After Hives: Evidence Limits
No clinical evidence shows that ipamorelin alone is a safe substitute after hives from another peptide or that it improves sleep and recovery.
GLP-1 drugs and skin: what JAAD flagged
A new JAAD editorial puts skin changes and medicolegal questions around semaglutide and tirzepatide on the dermatology agenda.
Oral semaglutide nanomicelles in mice
A mouse study tests dual-transporter-targeted semaglutide nanomicelles. The early result is about delivery science, not a new treatment.
Regenerative Peptides for Tissue Repair
A 2026 review finds limited human evidence for many regenerative peptides used for tissue repair and chronic pain claims.
Tirzepatide weight loss outcomes in PCOS
A UK real-world study found similar 10-month tirzepatide weight loss in women with self-reported PCOS and women without PCOS.
Retatrutide and Heart-Risk Biomarkers
A post hoc analysis of two retatrutide Phase 2 trials found large drops in atherogenic lipoproteins and CRP, not proof of fewer cardiovascular events.